Orexo/Meda's Edluar gains US approval for insomnia
This article was originally published in Scrip
The US FDA has approved Orexo's Edluar (sublingual zolpidem) 5mg and 10mg for the treatment of short-term insomnia that is characterised by difficulties with sleep initiation. The product, which was previously known as Sublinox, is expected to be launched in the second half of this year.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.